Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Value of Biosimilars and the Role of Interchangeability
A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
Now Viewing
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low?
- How can the uptake of biosimilars into health systems be improved?
- Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?
- What has your experience been like switching from adalimumab reference product to biosimilars?
- How can switching from adalimumab reference product to biosimilars be improved in the future?
Related Videos
Related Content
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Article
Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
